Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

abc

Lean Right

Factuality

Ownership

A woman diagnosed with a brain tumor when she was a child, a neuroblastoma, remains without trace of the tumor 18 years after having been treated with T-cell therapy with a chimeric antigen receptor (CAR-T) without the need for additional treatments. In addition, the patient has given birth to two healthy babies.The findings, published in 'Nature Medicine ', could represent the longest known remission of a person with cancer treated with CAR-T t…

Eldiario.es

Lean Left

Factuality

Ownership

A group of U.S. researchers who launched a trial between 2004 and 2009 with patients with neuroblastoma documents the longest remission of the disease recorded in these therapies and opens a door to hope: "The treatments have been greatly improved"

Nature

Center

Factuality

Ownership

Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma

In a phase 1 clinical trial open to accrual from 2004 to 2009, we treated children with neuroblastoma with Epstein–Barr virus (EBV)-specific T lymphocytes and CD3-activated T cells—each expressing chimeric antigen receptors (CARs) targeting GD2 but without an embedded co-stimulatory sequence (first-generation CARs). These CARs incorporated barcoded sequences to track each infused population. We previously reported outcomes up to 5 years and now …

Stemwell Science News

Factuality

Ownership

Long-Term Outcomes of GD2-Directed CAR-T Cell Therapy in Patients with Neuroblastoma

Investigators describe the longest reported survival after CAR T therapy for active malignancy, demonstrating that GD2 CAR-ATC/VST therapy could safely produce up to more than 18 years of complete remission in children with refractory/relapsed neuroblastoma. [Nature Medicine] Full Article

ecnetnews.com

Factuality

Ownership

CAR T-cells Achieve Historic 18-Year Remission in Nerve Cancer Patient

A groundbreaking cancer therapy utilizing genetically engineered immune cells, known as CAR T-cells, has achieved an unprecedented milestone by keeping a patient free from a potentially deadly nerve tumor for an astonishing 18 years. This remarkable case represents the longest documented complete remission in a patient treated with CAR T-cell therapy. Medical experts acknowledge this achievement as a significant breakthrough in cancer treatment.…

Medical Xpress

Factuality

Ownership

Patient with nerve cell cancer in remission for 18 years following CAR-T therapy

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with chimeric antigen receptor (CAR) T cell therapy and without requiring any additional treatments. The findings are published in Nature Medicine.